Key facts
- This page summarizes ATP Life Science Ventures, L.P.'s Form 4 filing for Akero Therapeutics, Inc. (AKRO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 30 Jun 2021, 16:31.
ATP Life Science Ventures, L.P. - 28 Jun 2021 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- AKRO
- Reported as of
- 28 Jun 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ Seth L. Harrison, for ATP Life Science Ventures, L.P., By: Seth L. Harrison, as director of ATP III GP, Ltd., its general partner
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
ATP Life Science Ventures, L.P. filed Form 4 for Akero Therapeutics, Inc. (AKRO) on 30 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKRO
transaction
Common Stock
Other
- Transaction value
- Shares
- -5,830,203
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 28 Jun 2021
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
ATP Life Science Ventures, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
The shares were distributed in a pro rata distribution to the limited partners of ATP Life Science Ventures, L.P. ("ATP," and formerly known as Apple Tree Partners IV, L.P.).
Footnote F2
The shares were directly held by ATP. ATP III GP, Ltd. ("ATP GP") is the sole general partner of ATP. Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP. ATP GP and Dr. Harrison disclaim beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein.